Extended Methods Section
The model stochastically simulates the progression to AIDS and death in a cohort of HIV-infected individuals and tracks the services they receive and selected health indicator outcomes. Each individual is realised independently and the properties of the individual and the timing of events are calculated probabilistically based on a series of rules and parametric distributions. The data used to parameterise the disease-progression part of the model are taken from several African studies, and it was decided that the characteristics of the cohort would reflect the current epidemiological conditions in eastern Zimbabwe.
Characteristics of the cohort
The composition of the cohort is based on the gender and age distribution of newly infected individuals in the Manicaland cohort study, situated in the eastern highlands of Zimbabwe, between 1998 and 2002 [1] (Table 1) . To capture a suitable range of stochastic effects, the number of individuals in the cohort for most simulations is 1000; the effects described in this paper and not sensitive to the size of the cohort.
Mortality from non-HIV/AIDS related causes among children is assumed to be: 53 per 1000 live births for infants (0-1years), and a total of 90 per 1000 live births die before their fifth birthday (deaths distributed exponentially with parameters 0.054 for 0-1
year-olds, and 0.010 for 1-4 year-olds) [2] . The chance of dying between ages 5 and 99 is Weibull distributed such that median life-expectancy in the absence of HIV/AIDS is 48.8 years for men and 52.5 years for women, as observed in the Manicaland cohort for uninfected individuals [3] (shape and scale parameters for males: 7 and 57.5; for females 7 and 61.8). 
Clinical progression
For the th i individual, the CD4 count ( The unit of ( ) t CD i 4 is number of cells per microlitre of peripheral blood ( ) 1 − l µ . A steady decline in square-root CD4 is theoretically [4] and clinically [5] justified and uses parameters that are directly comparable to those in evaluated in several statistical analyses [6, 7, 8] . Although this is not likely to be a good description of CD4 decline immediately after infection, it should be sufficient for our analyses, which concern using CD4 count information once the infection is established. Bayesian shrinkage estimate [7] of the variance in the rate of decline of CD4 counts.
This means that in the model 68% of individuals younger than 35 years are assigned rates of CD4 decline within one standard deviation of the mean (0.3 to 2.3) and of the rest, half are assigned a rate of decline less than 0.3 (slow-progressors) and half are assigned a rate of decline greater than 2.3 (fast-progressors) (Figure 1(a) ). The value of 0 .
is chosen to reproduce shorter survival times for older people [10, 11] .
Each measurement of CD4 count is modelled as an observation of ( ) t CD i 4 plus random error (with standard deviation m σ ). The error derives partly from technical factors [12] , but mostly from short-timescale physiological fluctuations in the true CD4 count [13, 14, 15] . In laboratory studies where counts have been repeated on the same blood sample and on blood samples taken within the same few weeks, the combined variation is estimated to have a standard deviation of approximately 50. In the model, it is assumed that this variation is distributed uniformly, with mean zero.
The value upon which the clinical decision is taken ( 
2
= n and f is the mean or the minimum. The relationship between clinical signs (WHO stage III or IV) and immunesuppression is not well characterised. To incorporate this uncertainty in the model, three alternative scenarios were defined ( Figure 2 ). Scenario I (which is used, unless specified otherwise) is based on observations from Uganda [16] and Ethiopia [17] (Double Weibull distribution with first shape and scale parameters 2. [16] and triangles show data points from a study in Ethiopia [17] .
Survival after CD4 count falls below 200 ( ) 1 − l µ is assumed to be exponentially distributed with a median survival of 11 months, in accordance with a review of studies from resource-poor settings [18] .
Survival from infection to death for young individuals has been estimated to be 10.9 years in Western populations [10] and 9.8 years in Uganda [11] , although some studies have indicated lower survival rates in other African populations (reviewed by Jaffar et al. [19] ). Despite being based on independent data sources, the model is in good agreement, generating a median survival of ~9.5years for individuals infected when younger than 35 years ( Figure 3 ). The shape of the survival distribution for those surviving ten years or more after infection has not been directly observed. In order that the model survival curve approximates a Weibull distribution, the number of individuals with very long survival times is limited by accelerating the rate of progression if they have not developed AIDS after ten years. This is done by replacing the rate of progression ( i b ) with a new stochastically sampled value from the same probability distribution, provided it is at least as great as the initial value. In 
Diagnosis of infection
Individuals may be diagnosed with HIV in one of three ways, whichever comes first.
Once the infection is diagnosed, clinical monitoring of the individual can begin (see below). If none of these events happen, the individual is not diagnosed and therefore does not enter care and cannot start treatment.
Individual falls pregnant and attends ante-natal clinic (ANC).
Recent estimates of fertility rates in Zimbabwe [20, 21] and measurements of sub-fertility over the course of infection [22] are used to capture patterns of ANC attendance (Table 2) . For each pregnancy, the probability that the women will attend an ante-natal clinic, have her infection diagnosed and be referred to the anti-retroviral treatment (ART) programme can be 10% ("poor referral" scenario; estimated to currently be the case in Zimbabwe) or 90% ("good referral" scenario). It is assumed that attendance at ANC is exactly six months before delivery.
Individuals go for voluntary counselling and testing (VCT).
It is assumed that the probability that an individual goes for VCT is constant over time. "Low VCT uptake" means that 5% of individuals (randomly selected) go for VCT and "High VCT uptake" means that 70% of individuals go for VCT. Individuals go for VCT at some time (uniformly distributed) before they would otherwise present at a clinic (see below). It is assumed that individuals that do not go for VCT are either geographically isolated from services or unwilling to attend for other reasons. High VCT uptake could be achieved following scale-up of services{Population Services International, 2006 #261}, including home-based testing [24] , or if policies are changed to allow routine 'opt-out' testing at all medical facilities [25, 26] .
Individual develops symptoms and goes to a clinic
The CD4 level at which an individual develops symptoms sufficiently severe to seek medical attention is determined by when the depletion of the immunesystem reaches a predetermined threshold. This threshold varies between individuals and is drawn stochastically from a distribution based on the CD4 levels of those attending a clinic in Cote d'Ivoire [27] : Weibull distribution, shape parameters 0.8, scale parameter 194.1 (Figure 4 ). Two alternative scenarios are also included, whereby individuals present at the clinic earlier (e.g. in response to minor symptoms [28, 29] Figure 4 The CD4 level at which individuals will present at a clinic if they have not already been diagnosed. The red line is the default scenario and is based on CD4 counts among those presenting at a clinic in Cote d'Ivoire [27] (white squares). The blue and the green lines are alternative scenarios, whereby individuals present at a clinic earlier or later, respectively.
Clinical Observation
Once the HIV infection is diagnosed, individuals can visit the ART provider (usually a doctor or nurse at a local or district-level clinic) so that their need for ART can be assessed. It is assumed that when an individual is first diagnosed (whether at ANC, VCT or when they develop symptoms sufficiently severe to seek care) they immediately visit the ART provider. At each visit to the ART provider, the date of the next appointment is arranged. The time to the next appointment can be determined by the CD4 count and/or age of the individual; seven different scenarios are used in the model ( Table 1 in the main text). Individuals may be lost-to-follow-up (e.g. due to out-migration, incapacity, forgetting etc.) and will not attend the next (or any subsequent) appointment. The assumed rate of loss is constant over time, so that for a set rate (e.g. 0.20), ~18% are lost in the first year, and of those that remain, 15% are lost the next year, then 12% in the year after, and so on. For most simulations, this rate is set to zero.
Decision to Start ART
At each visit to the ART provider a decision is taken about whether the individual will start ART. The algorithm is to start ART if certain criteria regarding clinical symptoms and CD4 measurements are met. A range of algorithms are used in the model ( Table   2 in the main text). The decision to start ART can be based entirely on whether or not the patient has severe symptoms ("syndromic initiation": code 1). The recommendations of the WHO [31] are to start ART if the CD4 count is below
if the patient already has severe symptoms (code 7).
The use of CD4 counts can be conditional on whether the individual has symptoms (codes 2, 3 and 4) and different thresholds for initiation can be used (codes 4 and 5).
If an additional CD4 count is taken (codes 8 and 9), then another appointment is scheduled for within a few weeks, and the decision to start ART is taken at the second appointment. has quantified three-year survival for individuals starting therapy, stratified by baseline CD4 and the presence of WHO stage III/IV symptoms [32] . The ART-LINC collaboration of cohorts also finds evidence that the risk of death is higher in lowincome settings in the first few months of ART, but similar to the rate in high-income countries later [33] . In the absence of a systematic aggregation of survival rates over a longer period from African cohorts, three survival scenarios were defined ("best", "medium" and "worst"). These scenarios are parameterised in the following way:
i.
First-year survival is equal to aggregated estimates from low-income settings [33] . The "medium" scenario uses the point estimate and the "best" and "worst" scenarios use the limits of the 95% confidence intervals.
ii. The relationship between CD4 count, symptoms and hazard of death after the first year is based on data from high-income countries [32] . In the "best" scenario, the hazard of mortality observed in the first three years of therapy is assumed to stay constant; in the default scenario it increases gradually; and in the pessimistic scenario the hazard of death increases sharply with time on ART.
Survival time is Weibull distributed for all scenarios ( Figure 5 ). The parameters for the survival time scenarios are given in Table 3 .
The "medium" scenario, which is used in simulations unless otherwise stated, produces four-year survival rates of ~75% for those starting with CD4 count below 50 and 90% for those starting with CD4 count between 200 and 349, which is in good agreement with longer-term analyses of the ART-LINC cohort data, which have not yet been published [34] . Figure 5 Survival from start of ART with "best", "medium" and "worst" assumptions, by presence or absence of symptoms and CD4 count at start of ART. Background survival is included for a male starting ART aged 35 years.
Pregnancy and mother-to-child transmission
Pregnant women that have had their infection diagnosed and have not been lost to follow-up are eligible to receive treatment to prevent mother-to-child transmission (PMTCT) if they are not already on ART. In Zimbabwe, it is estimated [2] that the probability that a women is able to receive treatment to prevent mother-to-child transmission is 30%. The probability that a woman accepts to receive therapy under these circumstances is estimated to be 50%.
In the model, the probability that a baby is infected by its HIV-positive mother is 24% if she has received PMTCT, and 32% if she has not. This approximates the case for 7-17 months of breastfeeding and treatment being a single dose of Nevirapine [35, 36] . The probability that a baby is infected from its mother who is permanently on ART is 4% [36] .
Following the recommendations of UNAIDS [36, 37] , in the model the additional mortality hazard for an infected baby in the absence of treatment is taken to be distributed as a double-Weibull (first shape and scale parameters 0.97 and 1.52, second shape and scale parameters 5.39 and 10, respectively, weighting to first 0.65). This distribution has two components; the first represents the fast progressors, who are infected in-utero and intrapartum; the second represents the slow progressors, who are infected during breast feeding.
A "child death" is counted if they die before their 15 th birthday. A child is assumed to be (maternally) orphaned if their mother dies whilst they are alive and before their eighteenth birthday.
Distribution Notation
If i U are uniform random deviates between 0 and 1, then: i Q are uniformly distributed between a and b , where: 
Further Results
Presented at clinic Referred from ANC Referred from VCT 0 In the upper panel, it is assumed that referral from ANC is low and uptake of VCT is low; in the lower panel, it is assumed that referral from ANC is high and uptake of VCT is high. ART is initiated with CD4 counts in the manner recommended by WHO (code 7; Table 2 in the main text). A 5% yearly drop-out from follow-up is assumed. (Figure 4) : the 'default' scenario is based on data [27] , the 'early' scenario represents individuals presenting at clinic is response to minor symptoms and the 'later' scenario represents individuals presenting at clinic after a longer delay. The measured outcomes are the mean CD4 count at which ART is begun (top panel) and the mean number of life-years saved per person that is treated (lower panel). Treatment is initiated using CD4 counts in the manner recommended by WHO (code 7; Table 2 in the main text). Individuals in care are monitored every six months and a 5% yearly drop-out from follow-up is assumed. Table 2 in the main text). (b) Population level. The effect of increasing opportunities for diagnosis on the average survival time on ART (triangles) and average lifeyears saved by ART (squares). Values shown are the difference (in years) relative to where referral from ANC is low and VCT uptake is low. The initiation rule is the WHO recommendations (code 7). In both panels, individuals are monitored every 6 months; 5% yearly drop-out from follow-up is assumed; ANC referral is assumed to be high and VCT uptake is assumed to be low. 0.9 0.9 0.9 0.9 0.9 0.9 0.9 7 0.9 0.9 0.9 0.9 0.9 0.9 0.9 8 0.9 0.9 0.9 0.9 0.9 0.9 0.9 9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 10 0.9 0.9 0.9 0.9 0.9 0.9 0.9 Table B : What is the expected impact of the alternative patient monitoring and ART initiation strategies? Key indicator outcomes for alternative initiation rules and intervals between scheduled appointments. In all cases, the values relate to a cohort of 1000 HIV-infected individuals. ANC referral is assumed to be high, VCT uptake is assumed to be low and there is a 5% yearly drop-out rate. Figure 2 ). Points are labelled with the initiation code ( Table 2 in the main text) to which they refer. Individuals are monitored for ART need every six months and there is a 5% yearly drop-out rate. Note that axis scales are different in each plot. [7] One CD4 count [9] Two CD4 counts (take min) [10] Two CD4 counts if close (take min) Initiation rule: Figure F : Is there an advantage in basing the decision to initiate ART on more than one CD4 cell count? Key indicator outcomes for alternative initiation rules. Rule 7 is initiation as per WHO recommendation using one CD4 count (code 7; Table 2 in the main text); rule 9 is the same but uses the minimum of two CD4 counts; and, rule 10 instead only uses a second CD4 count if the first is close to the appropriate threshold (see Table 2 in the main text for details). Appointments are scheduled for every 6 months, ANC referral is assumed to be high and VCT uptake is assumed to be low and there is a 5% yearly drop-out rate. 
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Figure G: How is the impact of ART programmes related to the intensity of patient monitoring (both frequency of scheduled appointments and the drop-out rate)?
Increase in life-expectancy at infection for ART programmes that initiate patients syndromically (black lines) or with CD4 cell count (grey lines). (a) Patients are scheduled to be monitored for the need for ART between every 24 months year and every month with no drop-out. (b) Patients are scheduled to be monitored every six months, but a fraction, between 0 and 50%, drop-out (i.e. do not attend the next appointment) every year. The rate of ANC referral is assumed to be 44% and VCT uptake is assumed to be 33%. Figure H : What is the difference in impact of ART programmes that use the alternative patient monitoring strategies? Comparison of different monitoring strategies (details in Table 1 in the main text) as (a) years saved per person (bars and numbers), and (b) total number of appointments (line), each given relative to scheduling appointment every 12 months. The initiation scenario is the WHO recommendation with CD4 counts (code 7, Table 2 in the main text), ANC referral is assumed to be high, VCT uptake is assumed to be low and there is 5% yearly drop-out from follow-up.
